Xponance Inc. Grows Position in Pfizer Inc. (NYSE:PFE)

Xponance Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 891,024 shares of the biopharmaceutical company’s stock after buying an additional 91,843 shares during the period. Xponance Inc.’s holdings in Pfizer were worth $25,653,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Moneta Group Investment Advisors LLC boosted its position in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares during the last quarter. Morgan Stanley boosted its position in Pfizer by 0.4% in the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares during the last quarter. Norges Bank purchased a new position in Pfizer in the fourth quarter worth about $3,150,472,000. Finally, Massachusetts Financial Services Co. MA boosted its position in Pfizer by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after purchasing an additional 5,185,453 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.1 %

Shares of NYSE PFE traded down $0.03 during trading hours on Thursday, hitting $25.39. 35,472,911 shares of the company traded hands, compared to its average volume of 42,406,477. The stock has a market capitalization of $143.77 billion, a price-to-earnings ratio of 70.25, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average price is $27.19 and its 200 day moving average price is $28.76. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the business earned $1.14 EPS. Pfizer’s revenue was down 41.3% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PFE has been the topic of several research reports. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.